Recent discoveries and developments of androgen receptor based therapy for prostate cancer

  title={Recent discoveries and developments of androgen receptor based therapy for prostate cancer},
  author={Elancheran Ramakrishnan and V Lenin Maruthanila and M. Ramanathan and Senthamaraikannan Kabilan and Rajlakshmi Devi and Ajaikumar B. Kunnumakara and Jibon Kotoky},
The main focus of this review is to discuss the discoveries and developments of various therapies for prostate cancer. The AR has played an important role in prostate cancer growth and functions. This review discusses several groups of drugs that have sparingly good anti-cancer activities, as well as a similar structure and behaviour. A recent new-generation AR antagonist, Enzalutamide (MDV3100), has been approved for the treatment of advanced/metastatic prostate cancer. Nonsteroidal… 

Figures from this paper

Recent development of targeted approaches for the treatment of breast cancer

Advances in understanding tumor biology, particularly signaling pathways, Hedgehog/Gli 1 signaling pathway, and inhibitors are considered to be important for bone metastasis and may provide vital information for the design and development of new strategies for efficacy, reduction of the side effects, and treatment strategies.

Sesamol and its derivative investigated as antiandrogen - A potential prevention to prostate cancer in rats

It is found that SM and its derivative (3’-MA) may prevent the development of PCa by androgen pathway through the use of STITCH and molecular docking.

Relugolix is the first and currently only Orally-Administered GnRH Receptor Antagonist Approved for the treatment of Prostate Cancer: A Review

Relugolix is the first (and currently only) orally-administered GnRH receptor antagonist approved for the treatment of prostate cancer-similar therapies such as degarelix require subcutaneous administration-and therefore provides a less burdensome therapeutic option for patients who might otherwise require clinic visits for administration by healthcare professionals.

In Silico Molecular Docking, Synthesis of 4-(4-benzoylaminophenoxy) Phenol Derivatives as Androgen Receptor Antagonists.

The present approach is simple and efficient for the synthesis of BAPP derivatives and the observed IC50 values of BAPPs were in good agreement with the glide scores obtained from the molecular docking.

Synthesis of thioether andrographolide derivatives and their inhibitory effect against cancer cells.

A series of novel thioether andrographolide derivatives synthesized by incorporating various aromatic (or heteroaromatic) substituents into C-12 or 14-OH exhibited better activity against prostate cancer cells (PC-3) than the parent compound.

Design, Synthesis, and Biological Evaluation of (E)-N'-((1-Chloro-3,4-Dihydronaphthalen-2-yl)Methylene)Benzohydrazide Derivatives as Anti-prostate Cancer Agents

A structural based molecular docking approach revealed the findings of (E)-N'-((1-chloro-3,4-dihydronaphthalen-2-yl)methylene)benzohydrazide derivatives, where the possible binding modes of the compounds with protein (PDB ID: 3V49) are shown.



Preclinical Development of ONC1-13B, Novel Antiandrogen for Prostate Cancer Treatment

ONC1-13B is a new promising antiandrogen demonstrating high efficacy in a preclinical model of prostate cancer, with lower potential for seizures and drug-drug interaction, and well suited for co-therapy with drugs that are known CYP3A substrates.

Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

The diarylthiohydantoins RD162 and MDV3100 are characterized, two compounds optimized from a screen for nonsteroidal antiandrogens that retain activity in the setting of increased androgen receptor expression that appear to be promising candidates for treatment of advanced prostate cancer.

ARN-509: a novel antiandrogen for prostate cancer treatment.

ARS-509 exhibits characteristics predicting a higher therapeutic index with a greater potential to reach maximally efficacious doses in man than current AR antagonists, and offers preclinical proof of principle for ARN-509 as a promising therapeutic in bothCastration-sensitive and castration-resistant forms of prostate cancer.

Novel agents in the management of castration resistant prostate cancer

It is increasingly evident that CRPC is a heterogeneous disease and an individualized approach directed at identifying primary involvement of specific pathways could maximize the benefit from targeted therapies.

Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects

The aim of this review is to summarize molecular mechanisms of castration resistance and provide an update in the development of novel agents and strategies to more effectively target the AR signaling pathway.

Androgen receptor as a therapeutic target.

  • Wenqing Gao
  • Biology, Chemistry
    Advanced drug delivery reviews
  • 2010

Recent developments in antiandrogens and selective androgen receptor modulators

Structural basis for antagonism and resistance of bicalutamide in prostate cancer

The three-dimensional structure demonstrates that the B ring of R-bicalutamide in the W741L mutant is accommodated at the location of the indole ring of Trp-741 in the WT AR bound to dihydrotestosterone.

Andrographolide targets androgen receptor pathway in castration-resistant prostate cancer.

Andrographolide can be developed as a potential therapeutic agent for prostate cancer by inhibition of androgen receptor signaling by down-regulating AR expression at both mRNA and protein levels, and inhibits transactivation of its target genes.

Combined androgen blockade for prostate cancer: Review of efficacy, safety and cost‐effectiveness

The feasibility of CAB with bicalutamide for the treatment of prostate cancer is discussed by reviewing the theoretical background of Cab and then the results of RCT conducted in the 1990s when the usefulness ofCAB was assessed.